Acumen Pharmaceuticals Aktie
WKN DE: A3CTP6 / ISIN: US00509G2093
19.03.2025 14:37:36
|
Acumen Pharma Reports Positive Topline Data For Sabirnetug From Phase 1 Study
(RTTNews) - Acumen Pharmaceuticals, Inc. (ABOS), a clinical-stage biopharmaceutical company, Wednesday announced topline data from Phase 1 study of its drug candidate sabirnetug, which is being developed for the treatment of Alzheimer's disease.
The study was designed to compare pharmacokinetics (PK) between subcutaneous (SC) and intravenous (IV) formulations of sabirnetug in healthy volunteers.
Results from the study showed that weekly SC administration of sabirnetug was well-tolerated with systemic exposure supporting further clinical development.
A Phase 2 study of sabirnetug dubbed ALTITUDE-AD in patients with early Alzheimer's disease is underway.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Acumen Pharmaceuticals Inc Registered Shsmehr Nachrichten
11.08.25 |
Ausblick: Acumen Pharmaceuticals zieht Bilanz zum abgelaufenen Quartal (finanzen.net) |
Analysen zu Acumen Pharmaceuticals Inc Registered Shsmehr Analysen
Aktien in diesem Artikel
Acumen Pharmaceuticals Inc Registered Shs | 1,73 | -2,26% |
|